Drugs / cisplating
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05430802 | Jan 2023 → Sep 2025 overdue | non-small cell lung carcinoma | Tang-Du Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cisplating | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05430802 ↗ |
| Route | Intravenous | “cisplating75mg/m2 d1 iv” NCT05430802 ↗ |